Value-chain Digitization in the Pharmaceutical Industry Is Causing Tectonic Shifts in ITO Strategy

Faced with the challenges imposed by the patent cliff, low drug approval rates, low R&D productivity, and increased competition in the high-volume generics market, the pharmaceutical industry must enable a two-pronged product and channel strategy. The former requires improving R&D productivity and drug approvals through smart analytics and personalized medicine, and the latter requires enabling new-age channels to reach customers. Both require technology as the key enabler across the value chain.

However, is the industry mature enough to embark on a value-chain digitization strategy? Do IT services providers have the necessary capability to partner the industry in taking this next-generation leap? This one-hour Webinar answered the following questions:

• What is the current status of technology enablement in the pharmaceutical value chain?
• What are the key imperatives within the pharmaceutical value chain that will be the demand drivers for ITO?
• Why should pharma CIOs start thinking about these transformational imperatives now?